1. Home
  2. UAMY vs MURA Comparison

UAMY vs MURA Comparison

Compare UAMY & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo United States Antimony Corporation

UAMY

United States Antimony Corporation

HOLD

Current Price

$5.03

Market Cap

829.0M

Sector

Industrials

ML Signal

HOLD

Logo Mural Oncology plc

MURA

Mural Oncology plc

HOLD

Current Price

$2.03

Market Cap

36.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
UAMY
MURA
Founded
1968
2013
Country
United States
Ireland
Employees
N/A
N/A
Industry
Metal Fabrications
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
829.0M
36.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
UAMY
MURA
Price
$5.03
$2.03
Analyst Decision
Strong Buy
Buy
Analyst Count
5
2
Target Price
$5.69
$6.00
AVG Volume (30 Days)
8.3M
224.8K
Earning Date
11-12-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$31,857,819.00
N/A
Revenue This Year
$159.13
N/A
Revenue Next Year
$228.42
N/A
P/E Ratio
N/A
N/A
Revenue Growth
177.97
N/A
52 Week Low
$1.21
$0.95
52 Week High
$19.71
$4.74

Technical Indicators

Market Signals
Indicator
UAMY
MURA
Relative Strength Index (RSI) 35.81 40.39
Support Level $5.16 $2.06
Resistance Level $6.95 $2.10
Average True Range (ATR) 0.53 0.01
MACD 0.05 -0.01
Stochastic Oscillator 3.28 25.00

Price Performance

Historical Comparison
UAMY
MURA

About UAMY United States Antimony Corporation

United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company. It has two operating segments: antimony and zeolite. Its products and services include antimony; silver; gold; zeolite products; and storage, handling, & packaging services. The company's geographical segments are the United States, Canada, and Mexico, of which the vast majority of its revenue comes from the United States.

About MURA Mural Oncology plc

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.

Share on Social Networks: